Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-22
2006-08-22
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07094756
ABSTRACT:
The present invention relates to the use of the A20-binding inhibitor of NF-κB activation (ABIN), or a functional fragment or variant thereof to protect against TNF-induced liver failure, such as viral hepatitis and alcoholic liver disease. More particularly, it relates to the prevention of the toxic effects of said diseases, including lethality, by overexpressing ABIN.
REFERENCES:
patent: 4186183 (1980-01-01), Steck et al.
patent: 4217344 (1980-08-01), Venlerberghe et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4261975 (1981-04-01), Fullerton et al.
patent: 4485054 (1984-11-01), Mezei et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4774085 (1988-09-01), Fidler
patent: 4797368 (1989-01-01), Carter et al.
patent: 4837028 (1989-06-01), Allen
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: WO 91/16024 (1991-10-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 97/37016 (1997-10-01), None
patent: WO 99/57133 (1999-11-01), None
patent: WO 03/000280 (2003-01-01), None
Kono et al., NADPH oxidase-derived free radicals are key oxidants in alchohol-induced disease, J. Clin. Invest., (2000), 106, p. 867-872.
De Valck et al., “A20, an inhibitor of cell death, self-associates by its zinc finger domain,” 384 FEBS Letters 61-64 (1996).
Fukushi, M., Homosapiens mRNA for HIV-I, Nef-associated factor 1 beta (Nafl bets),: Emhum Database Entry HSA011896, Accession No. AJ011896, Oct. 14, 1998, XP002124741.
Fukushi, M., et al., “NAF1 alpha protein (KIAA0113 protein),” Trembl Database Entry A15025, Accession No. Q15025, Nov. 1, 1996, XP02124740.
Hendrick, B.D., et al., “An X-linked homologue of the autosomal imprinted gene NF127 escapes X chromosome inactivation,” Emhum Database Entry HS4131510; Accession No. U41315, May 19, 1996, XP002125387.
Heyninck et al, “The Zinc Finger Protein A20 Inhibits TNF-induced NF-kB-dependent Gene Expression by interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-kB-inhibiting Protein ABIN,” 145 The Journal of Cell Biology 1471-1482 (1999).
Miyajima, N., et al., “Human mRNA for KIAA 0133 gene, partial coding sequence,” Emhum Databse Entry HSORFA2, Accession No. D30755, May 21, 1994, XP002124739.
Nomura et al., “mRNA for ORF, partial CDS (fragment),” Trhum Database Entry Q15025; Nov. 1, 1996, Accession No. Q15025, XP002080989.
Song et al., “The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kB activation,” 93 Proc. Natl. Acad. Sci. USA 6721-6725 (1996).
Yen, R.W.C., et al., “DNA-methyltransferase,” Swissprot Database Entry MTDM—Human; May 1, 1992, Accession No. P26358, XP002080990.
PCT International Preliminary Examination Report, PCT/BE99/00055, DATED Aug. 10, 2000, 8 pages.
PCT International Search Report, PCT/BE99/00055, dated Dec. 29, 1999, 3 pages.
Fukushi et al., (Nov. 1, 1996) Acc. No. Q15025, SPTREMBL—17 database, GenCore Version 4.5, Accessed May 8, 2002.
Gupta, et al. (Mar. 1, 2001) Acc. No. Q9HIJ3, SPTREMBL—17, GenCore Version 4.5, Accessed May 8, 2002.
Beyaert et al., A20 and A20-Binding Proteins as Cellular Inhibitors of Nuclear Factor-kB-Dedpendant Gene Expression and Apoptosis, Biochemical Pharmacology, 2000, pp. 1143-1151, vol. 60.
Baldwin, Jr. et al., The transcription factor NF-kB and human disease, The Journal of Clinical Investigation, Jan. 2001, pp. 3-6, Jan. 2001, vol. 107, No. 1.
Ghosh et al., Missing Pieces in the NF-kB Puzzle, Cell, Apr. 2002, pp. S81-S96, vol. 109.
Heyninck et al., Structure-function analysis of the A20-binding inhibitor of NF-kB activation, ABIN-I, FEBS Letters, 2003, pp. 135-140, vol. 536.
Ngo et al., Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox, The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 491-495.
Yamamoto et al., Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer, The Journal of Clinical Investigation, Jan. 2001, pp. 135-142, vol. 107, No. 2.
Zhang et al., Environment-dependent residue contact energies for proteins, PNAS, Mar. 14, 2000, pp. 2550-2555, vol. 97, No. 6.
PCT International Search Report, PCT/EP02/07154, dated Dec. 16, 2002.
PCT International Preliminary Examination Report, PCT/EP02/07154, Apr. 3, 2003, 7 pages.
Kaplowitz, Neil, “Hepatology Highlights;” Hepatology, Aug. 2005, pp. 247-248, vol. 42, No. 2.
Wullaert et al., “Adenoviral Gene Transfer of ABIN-1 Protects Mice from TNF/Galactosamine-Induced Acute Liver Failure and Lethality,” Hepatology, Aug. 2005, pp. 381-389, vol. 42, No. 2.
Beyaert Rudi
Delaei Filip
Libert Claude
Van Huffel Sofie
Wielockx Ben
Carlson Karen Cochrane
Rooke Agnes
Vlaams Interuniversitair Instituut Voor Biotechnologie VZW
LandOfFree
Abin-mediated hepatitis protection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Abin-mediated hepatitis protection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abin-mediated hepatitis protection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3613467